DaVita HealthCare Partners Inc. (NYSE:DVA) was the recipient of unusually large options trading on Friday. Investors acquired 2,129 put options on the stock. This is an increase of 610% compared to the typical volume of 300 put options.

Shares of DaVita HealthCare Partners (DVA) opened at $61.11 on Monday. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.40 and a quick ratio of 1.35. The company has a market capitalization of $11,563.97, a PE ratio of 17.46, a PEG ratio of 12.32 and a beta of 0.97. DaVita HealthCare Partners has a 52 week low of $52.51 and a 52 week high of $70.16.

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.13). The company had revenue of $3.92 billion during the quarter, compared to the consensus estimate of $3.91 billion. DaVita HealthCare Partners had a net margin of 3.40% and a return on equity of 13.31%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $0.95 earnings per share. sell-side analysts predict that DaVita HealthCare Partners will post 3.42 earnings per share for the current year.

DaVita HealthCare Partners announced that its Board of Directors has approved a share repurchase plan on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in shares. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its stock is undervalued.

Hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its stake in shares of DaVita HealthCare Partners by 4.4% in the 3rd quarter. Rhumbline Advisers now owns 321,155 shares of the company’s stock valued at $19,073,000 after acquiring an additional 13,471 shares during the last quarter. Riverhead Capital Management LLC increased its stake in shares of DaVita HealthCare Partners by 10.6% in the 2nd quarter. Riverhead Capital Management LLC now owns 112,506 shares of the company’s stock valued at $7,286,000 after acquiring an additional 10,775 shares during the last quarter. Founders Capital Management LLC increased its stake in shares of DaVita HealthCare Partners by 2.3% in the 3rd quarter. Founders Capital Management LLC now owns 95,939 shares of the company’s stock valued at $5,698,000 after acquiring an additional 2,115 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its stake in shares of DaVita HealthCare Partners by 1,987.3% in the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock valued at $2,448,000 after acquiring an additional 39,746 shares during the last quarter. Finally, Speece Thorson Capital Group Inc. increased its stake in shares of DaVita HealthCare Partners by 14.5% in the 3rd quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock valued at $19,075,000 after acquiring an additional 40,667 shares during the last quarter. 85.34% of the stock is owned by institutional investors.

Several brokerages have weighed in on DVA. KeyCorp reissued a “hold” rating on shares of DaVita HealthCare Partners in a report on Monday, November 13th. Robert W. Baird reissued a “hold” rating and set a $63.00 price objective on shares of DaVita HealthCare Partners in a report on Friday, November 10th. Bank of America dropped their price objective on DaVita HealthCare Partners from $75.00 to $66.00 and set a “neutral” rating for the company in a report on Wednesday, November 8th. Royal Bank Of Canada dropped their price objective on DaVita HealthCare Partners from $64.00 to $60.00 and set a “sector perform” rating for the company in a report on Wednesday, November 8th. Finally, Wolfe Research raised DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a report on Monday, October 23rd. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $63.00.

TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/04/davita-healthcare-partners-target-of-unusually-large-options-trading-dva.html.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.